Wanbury Ltd.
Snapshot View

64.95 -2.05 ▼-3.1%

20 May 2022, 04:01:00 PM
Volume: 3,820

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.wanbury.com
Market Cap 212.98 Cr.
Enterprise Value(EV) 316.74 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) -3.07 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share -33.10 Trailing Twelve Months Ending 2021-12
Price to Book Value -1.96 Calculated using Price: 64.95
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 3.27 Cr. 32,665,498 Shares
FaceValue 10
Company Profile

Wanbury was incorporated in 1990 as a private limited company under the name of Pearl Distributors Private Limited. The name of the company was changed to 'Pearl Organics Private Limited on January 17, 1991 and the company was converted into a public limited company on August 6, 1991.

Wanbury is the fastest growing pharma company amongst top 100 companies in India as per ORG-IMS has strong presence in domestic branded formulations. Wanbury’s major thrust area also lies in Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS). It has a presence in Spain through its branded formulation business - Cantabria Pharma S. L acquired in 2006.

The company is having 3 API manufacturing facilities including 2 US FDA approved multi-product API facilities for regulated markets.

Product range of the company includes:

  • Coriminic table
  • Cpink table
  • Nock 2 tab
  • Senasof tab
  • Zevanuron
  • Rabiplus cap
  • Folinine
  • Cpink-s
  • Nuture
  • Adtrol 200mg

Milestones:

2008Wanbury opened an office in Zurich, Switzerland for its CRAMS business. Wanbury incorporated Wanbury Global FZE in Middle East for expanding its global business.Wanbury achieved consolidated turnover of Rs. 630 crore for 18 months period ended 30th September 2008. Rabiplus was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs.13.8 crores in launch Year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2007Doctor’s Organics Chemicals merged with Wanbury. Wanbury entered into a strategic association with Bravo Healthcare Wanbury incorporated Ningxia Wanbury Fine Chemicals Co to source raw materials from China. Wanbury approved as preferred Vendor by Pfizer (US) for Contract Research and Manufacturing Services (CRAMS). Cpink was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs. 11 crores in launch year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2006Wanbury achieved 100 crore turnover. Pharmaceutical Products of India (PPIL) merged with Wanbury pursuant to BIFR order. Wanbury acquired Cantabria Pharma S.L. with presence in ethical branded formulations in the Spanish market. Wanbury crossed 1000 employees mark. Wanbury became the world’s largest producer of Metformin with production of 4500 MT.

2005Wanbury acquired Doctor’s Organics and Chemicals, having a US FDA approved facility for manufacturing multi-product API’s.

2004Wander merged with Pearl Organics Limited and Pearl Organics renamed as Wanbury Wanbury set up its R & D center in Navi Mumbai for API. Wanbury started using SAP as a business transaction system.

2002Pearl Organics got US FDA approval for Patalganga plant.

1996Pearl Organics entered into a strategic alliance with Wyckoff Chemicals (US) to market its API in US.

1995Pearl Organics acquired plant of Brij Chemicals Pvt at Patalganga (Maharashtra).

1992Pearl Organics established its first plant in Tarapur for manufacturing API’s.

1991Pearl Distributors Pvt went public and was renamed as Pearl Organics.

1990Incorporated as Pearl Distributors Pvt

Achievements/ recognition:-

  • Wanbury ranks 47th as per ORG-IMS (Jan-2009) 
  • Cpink awarded “Best Brand Launch' by ORG IMS (06-07)  
  • Rabiplus awarded “Best Brand Launch' by ORG IMS (07-08) 
  • World's largest producer of Metformin
  • Fastest growing company amongst top 100 companies in the domestic market as per ORG IMS.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-3.06%
1 Week
-7.21%
1 Month
-23.23%
3 Month
-31.09%
6 Month
-11.87%
1 Year
-37.16%
2 Year
+277.62%
5 Year
+24.78%
10 Year
+259.83%
9 years 2013-03 2014-09 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%)
Return on Capital Employed (%) -12.92 -31.06 13.85 15.27 70.48 -2.00 50.26 444.45
Return on Assets (%) -11.03 -21.66 0.80 -1.82 15.57 -9.44 -9.00 23.10 -4.51

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds -48 -192 -194 -189 -153 -185 -209 -143 -156 -108
Non Curr. Liab. 347 312 298 251 160 106 130 108 84 83
Curr. Liab. 447 259 265 299 402 348 362 311 355 379
Minority Int. 27 27 27 27
Equity & Liab. 773 406 396 388 409 269 283 275 284 354
Non Curr. Assets 583 219 215 224 217 192 185 182 182 185
Curr. Assets 190 187 181 164 192 78 98 94 101 169
Misc. Exp. not W/O
Total Assets 773 406 396 388 409 269 283 275 284 354

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 459 662 250 423 434 371 391 367 393 497
Other Income 5 11 6 1 90 77 12 46 5 2
Total Income 464 673 256 425 524 448 403 414 397 499
Total Expenditure -491 -638 -229 -391 -415 -439 -378 -389 -377 -477
PBIDT -27 35 28 34 108 9 25 25 20 23
Interest -37 -48 -19 -32 -36 -31 -40 -33 -23 -22
Depreciation -23 -23 -5 -9 -10 -10 -10 -10 -10 -11
Taxation 0 -3 -1 0 0 0 0 0 0
Exceptional Items -89 83
PAT -87 -128 3 -7 62 -32 -25 64 -13 -10
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit -87 -128 3 -7 62 -32 -25 64 -13 -10
Adjusted EPS -50 -64 2 -4 27 -13 -10 26 -5 -4

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 9 87 68 40 43 43 32 30 44 17
Cash Fr. Inv. -32 -21 -6 -5 -20 -13 -1 -3 64 8
Cash Fr. Finan. 24 -64 -71 -30 -28 -27 -33 -27 -108 -17
Net Change 2 3 -9 5 -5 3 -2 0 0 7
Cash & Cash Eqvt 7 10 1 6 2 5 3 3 3 10

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 52.13 52.13 52.09 52.09 52.09 39.90 39.90 39.89 39.89
Public 47.87 47.87 47.91 47.91 47.91 60.10 60.10 60.11 60.11
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 76.76 76.76 76.76 76.76 76.76 76.76 76.76 76.76 76.76

Announcements View Details

Fri, 20 May 2022
Board Meeting Intimation for Notice Of Board Meeting For Approving The Audited Financial Results & Audited Financial Statements Of The Company For The Last Quarter And Financial Year Ended 31St March 2022.
WANBURY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/06/2022 inter alia to consider and approve Notice is hereby given pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that the meeting of the Board of Directors of Wanbury Limited is scheduled to be held on Wednesday 22nd June 2022 inter-alia to consider and approve the following:1. Audited Financial Results (Standalone & Consolidated) for the last quarter and financial year ended 31st March 2022.2. Audited Financial Statements (Standalone & Consolidated) for the financial year ended 31st March 2022.Further as per Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 the trading window for dealing in Securities of the Company shall remain closed for the Companys Directors/Officers/Key Managerial Personnel/Designated Employees of the Company w.e.f. 1st April 2022 till the close of business hours on 24th June 2022
Fri, 15 Apr 2022
Certificate Under Regulation 40(9) Of The Listing Regulations For The Year Ended On 31St March 2022.
Pursuant to Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith the Compliance Certificate for the period from1s1 April 2021 to 31st March 2022 received from Ms. Kala Agarwal Practicing Company Secretary. Kindly take the same on your records and acknowledge the receipt.
Fri, 08 Apr 2022
Large Corporate Entity_Initial
Pursuant to the SEBI Circular No.: SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018 regarding Fund Raising by Issuance of Debt Securities by Large Entities; this is to confirm that the Company does not fall in the criteria mentioned under the said Circular and therefore does not qualify as Large Corporate.Kindly take the same on your records and acknowledge the receipt.

Technical Scans View Details

Fri, 20 May 2022
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Closing Below Previous Low Closing Below Previous Low
Closing Below Previous Low for 3 days Closing Below Previous Low for 3 days

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%